MA30226B1 - Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique. - Google Patents

Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.

Info

Publication number
MA30226B1
MA30226B1 MA31188A MA31188A MA30226B1 MA 30226 B1 MA30226 B1 MA 30226B1 MA 31188 A MA31188 A MA 31188A MA 31188 A MA31188 A MA 31188A MA 30226 B1 MA30226 B1 MA 30226B1
Authority
MA
Morocco
Prior art keywords
therapeutic use
cytotoxic agents
tomaymycin derivatives
novel tomaymycin
novel
Prior art date
Application number
MA31188A
Other languages
English (en)
Inventor
Laurence Gauzy
Robert Zhao
Yonghong Deng
Wei Li
Herve Bouchard
Ravi V J Chari
Alain Commercon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35953949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30226(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA30226B1 publication Critical patent/MA30226B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de tomaymycine de formule (I), leur procédé de préparation et leur utilisation thérapeutique.
MA31188A 2006-01-25 2008-08-19 Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique. MA30226B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06290154A EP1813614B1 (fr) 2006-01-25 2006-01-25 Agents cytotoxiques comprenant de nouveaux dérivés de Tomaymycine

Publications (1)

Publication Number Publication Date
MA30226B1 true MA30226B1 (fr) 2009-02-02

Family

ID=35953949

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31188A MA30226B1 (fr) 2006-01-25 2008-08-19 Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.

Country Status (39)

Country Link
US (1) US8163736B2 (fr)
EP (4) EP1813614B1 (fr)
JP (1) JP5116696B2 (fr)
KR (1) KR101428112B1 (fr)
CN (1) CN101374846B (fr)
AR (1) AR059201A1 (fr)
AT (1) ATE527262T1 (fr)
AU (1) AU2007209072C1 (fr)
BR (1) BRPI0707264A2 (fr)
CA (1) CA2635482C (fr)
CR (1) CR10149A (fr)
CY (2) CY1112495T1 (fr)
DK (2) DK1813614T3 (fr)
DO (1) DOP2007000016A (fr)
EA (1) EA017196B1 (fr)
EC (1) ECSP088632A (fr)
ES (2) ES2374964T3 (fr)
GT (1) GT200800147A (fr)
HN (1) HN2008001103A (fr)
HR (2) HRP20140307T1 (fr)
IL (1) IL192472A0 (fr)
MA (1) MA30226B1 (fr)
ME (1) ME01814B (fr)
MX (1) MX2008009582A (fr)
MY (1) MY157715A (fr)
NI (1) NI200800207A (fr)
NO (1) NO341074B1 (fr)
NZ (1) NZ569789A (fr)
PE (1) PE20071110A1 (fr)
PH (1) PH12011502704A1 (fr)
PL (2) PL1813614T3 (fr)
PT (2) PT1813614E (fr)
RS (2) RS52060B (fr)
SI (2) SI1813614T1 (fr)
TN (1) TNSN08283A1 (fr)
TW (1) TWI389909B (fr)
UA (1) UA97794C2 (fr)
WO (1) WO2007085930A1 (fr)
ZA (1) ZA200805649B (fr)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
PT2019104E (pt) 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
GB0819097D0 (en) * 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CA3014224C (fr) 2009-02-05 2022-05-24 Immunogen, Inc. Derives de benzodiazepine-indoline et procedes de preparation des derives
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
CN103068405A (zh) 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
PT2528625E (pt) * 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
FR2963007B1 (fr) * 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
WO2012145112A2 (fr) * 2011-04-18 2012-10-26 Immunogen, Inc. Nouveaux dérivés de maytansinoïdes comprenant un lieur sulfoxyde
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US9399641B2 (en) 2011-09-20 2016-07-26 Medimmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
CA2850373C (fr) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines et conjugues cibles
CA2850375C (fr) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines et conjugues cibles
JP6104257B2 (ja) * 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850264C (fr) 2011-10-14 2019-11-05 Medimmune Limited Pyrrolobenzodiazepines
RU2691698C2 (ru) 2012-02-24 2019-06-17 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Антитела против sez6 и способы их применения
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
CN104822656B (zh) 2012-05-15 2018-05-01 西雅图基因公司 自稳定接头偶联物
WO2013177481A1 (fr) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazépines et leurs conjugués
KR20150027829A (ko) 2012-07-09 2015-03-12 제넨테크, 인크. 항-cd22 항체를 포함하는 면역접합체
BR112015000437A2 (pt) 2012-07-09 2017-06-27 Genentech Inc imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
HK1211208A1 (zh) 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
EP2906249B1 (fr) 2012-10-12 2018-06-27 MedImmune Limited Synthèse et intermédiaires de dérivés de pyrrolobenzodiazépine pour conjugaison
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
PT2906248T (pt) 2012-10-12 2019-03-04 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
EP2745876A1 (fr) 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Dérivés d'éther d'aminoalkyle de phenyle substitués par substituents hydroxy aliphatique
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
MX2015010777A (es) 2013-03-14 2016-04-25 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4.
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
CA2922529A1 (fr) 2013-08-28 2015-03-05 Stemcentrx, Inc. Nouveaux modulateurs sez6 et procedes d'utilisation
WO2015028850A1 (fr) * 2013-09-02 2015-03-05 Hangzhou Dac Biotech Co., Ltd Nouveaux agents cytotoxiques pour la conjugaison de médicaments avec la molécule de liaison cellulaire
BR112016004450A2 (pt) 2013-09-17 2017-10-17 Genentech Inc métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
KR20160097336A (ko) 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
AR098743A1 (es) 2013-12-13 2016-06-08 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
MX2016010295A (es) 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
EP3107576A4 (fr) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anticorps anti-dll3 et conjugués de médicaments destinés à être utilisés dans un mélanome
JP6417421B2 (ja) 2014-02-28 2018-11-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 荷電連結体及び共役体のためのその使用
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
GB201407816D0 (en) 2014-05-02 2014-06-18 King S College London Pyrrolobenzodiazepine Compounds
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
WO2016008112A1 (fr) 2014-07-16 2016-01-21 Medshine Discovery Inc. Lieurs et application à des conjugués anticorps-médicament (acd) associée
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
MA40539A (fr) * 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
CR20170111A (es) 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
EP3189057A1 (fr) 2014-09-03 2017-07-12 ImmunoGen, Inc. Dérivés de benzodiazépine cytotoxique
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
SI3191135T1 (sl) 2014-09-12 2021-01-29 Genentech, Inc. Anti-HER2 protitelesa in imunokonjugati
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
CA2957148A1 (fr) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugues comprenant des anticorps anti-her2 et des pyrrolobenzodiazepines
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
TW201632531A (zh) 2015-01-14 2016-09-16 必治妥美雅史谷比公司 苯二氮呯二聚物，其結合物及製造與使用方法
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
US9504694B2 (en) * 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
JP6957035B2 (ja) 2015-04-10 2021-11-02 トーマス・ジェファーソン・ユニバーシティ 対象への移植用の免疫原性拡散チャンバおよびその調製方法
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EP3307749A4 (fr) 2015-06-15 2019-06-19 Hangzhou Dac Biotech Co., Ltd Lieurs hydrophiles pour conjugaison
AU2016284340A1 (en) 2015-06-23 2018-02-08 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
CA2991973C (fr) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Lieurs de pontage pour la conjugaison d'une molecule de liaison cellulaire
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3778602B1 (fr) 2015-07-21 2023-07-12 ImmunoGen, Inc. Procédés de préparation de dérivés de benzodiazépine cytotoxique
EP4477269A3 (fr) 2015-09-20 2025-03-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Anticorps monoclonaux spécifiques du récepteur de facteur de croissance des fibroblastes 4 (fgfr4) et leurs procédés d'utilisation
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3433278A4 (fr) 2016-03-25 2019-11-06 Seattle Genetics, Inc. Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
EP4656204A3 (fr) 2016-04-15 2026-06-03 BioAtla, Inc. Anticorps anti-axl, fragments d'anticorps et leurs immunoconjugués et leurs utilisations
EP3454864A4 (fr) 2016-04-21 2021-01-13 Abbvie Stemcentrx LLC Nouveaux anticorps anti-bmpr1b et méthodes d'utilisation
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (fr) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps anti-nouveau récepteur variable d'antigène (vnar) et conjugués d'anticorps ciblant des antigènes tumoraux et viraux
WO2017194568A1 (fr) 2016-05-11 2017-11-16 Sanofi Schéma de traitement utilisant un anticorps immunoconjugué anti-muc1 à base de maytansinoïde pour le traitement des tumeurs
EP4122958A1 (fr) 2016-05-13 2023-01-25 BioAtla, Inc. Anticorps anti-ror2, fragments d'anticorps, leurs immunoconjugués et leurs utilisations
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
WO2017214182A1 (fr) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Anticorps entièrement humain ciblant pdi pour l'immunothérapie anticancéreuse
AU2017305170A1 (en) 2016-08-02 2019-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
KR20240010534A (ko) 2016-08-09 2024-01-23 씨젠 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CA3036983A1 (fr) 2016-11-21 2018-05-24 Cureab Gmbh Anticorps anti-gp73 et immunoconjugues
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
EP3559038B1 (fr) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Anticorps humain specifiques pour flt3 et leur modes d'utilisation
WO2018146199A1 (fr) 2017-02-08 2018-08-16 Adc Therapeutics Sa Conjugués anticorps-pyrrolobenzodiazépine
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
WO2018193102A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polythérapie avec un conjugué anticorps anti-axl-médicament
WO2018195243A1 (fr) 2017-04-20 2018-10-25 Immunogen, Inc. Dérivés de benzodiazépine cytotoxiques et leurs conjugués
US11389480B2 (en) 2017-05-19 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
WO2019005208A1 (fr) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps de la mésothéline humaine et utilisations dans une thérapie anticancéreuse
WO2019006280A1 (fr) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Anticorps monoclonaux humains spécifiques de cd33 et leurs procédés d'utilisation
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
ES3075078T3 (es) 2017-09-20 2026-07-27 Ph Pharma Co Ltd Análogos de tailanstatina
CA3177215C (fr) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Conjugue anticorps-derive de pyrrolobenzodiazepine
JPWO2019088270A1 (ja) * 2017-11-02 2020-12-03 宇部興産株式会社 蛋白分解酵素の双頭型阻害剤
ES2920123T3 (es) 2017-11-14 2022-08-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina
WO2019133652A1 (fr) 2017-12-28 2019-07-04 Immunogen, Inc. Dérivés de benzodiazépine
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) * 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20210283141A1 (en) 2018-05-25 2021-09-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
JP7459043B2 (ja) 2018-07-12 2024-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
WO2020025108A1 (fr) 2018-07-31 2020-02-06 Astrazeneca Ab Lieurs et conjugués
CA3106544A1 (fr) 2018-08-08 2020-02-13 Mitchell Ho Anticorps monoclonaux a haute affinite ciblant le glypicane-2 et leurs utilisations
WO2020079239A1 (fr) 2018-10-19 2020-04-23 Medimmune Limited Conjugués de pyrrolobenzodiazépine
KR20210081350A (ko) 2018-10-19 2021-07-01 메드임뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
CN113302207B (zh) 2018-11-16 2025-05-13 维尔托索宾科公司 Cd38和icam1抗体及其用途
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
US20220347309A1 (en) 2018-12-19 2022-11-03 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance
IL312067B2 (en) 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
US20220096641A1 (en) * 2019-01-03 2022-03-31 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
AU2020206308B2 (en) 2019-01-08 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
WO2020154150A1 (fr) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux à haute affinité ciblant le glypicane-1 et procédés d'utilisation
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
US20230094471A1 (en) 2019-03-29 2023-03-30 Immunogen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN110483504B (zh) * 2019-08-02 2022-04-26 桂林理工大学 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
EP4045511A1 (fr) * 2019-10-16 2022-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Détection visuelle de réticulations d'adn induites par pbd
CA3156761A1 (fr) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanocorps a haute affinite ciblant b7h3 (cd276) pour traiter des tumeurs solides multiples
WO2021080608A1 (fr) 2019-10-25 2021-04-29 Medimmune, Llc Fraction ramifiée destinée à être utilisée dans des conjugués
EP4041769A1 (fr) 2019-12-12 2022-08-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Conjugués anticorps-médicament spécifiques à cd276 et leurs utilisations
US20230097908A1 (en) 2020-01-22 2023-03-30 Medimmune Limited Compounds and conjugates thereof
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
KR102927945B1 (ko) 2020-03-27 2026-02-23 어비디티 바이오사이언시스 인크. 근이영양증의 치료용 조성물 및 방법
AU2021251875A1 (en) 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2022093745A1 (fr) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps à domaine unique ciblant une protéine de spicule de coronavirus responsable du sars et leurs utilisations
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
IL305886A (en) 2021-03-18 2023-11-01 Seagen Inc Selective release of drugs from internalized conjugates of biologically active compounds
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2022232612A1 (fr) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanocorps spécifiques du virus de lassa et leurs méthodes d'utilisation
CA3216228A1 (fr) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps a domaine unique heterospecifiques ciblant pd-l1 pour le traitement de tumeurs solides
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
GB202110726D0 (en) 2021-07-26 2021-09-08 Cambridge Entpr Ltd Conjugating reagents and conjugates thereof
EP4401792A4 (fr) 2021-09-16 2025-12-03 Avidity Biosciences Inc Compositions et méthodes de traitement d'une dystrophie musculaire facio-scapulo-humérale
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
US20230279120A1 (en) 2021-11-09 2023-09-07 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
PE20242350A1 (es) 2022-05-03 2024-12-16 Genentech Inc Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
GB202207691D0 (en) 2022-05-25 2022-07-06 Cambridge Entpr Ltd Quinone protected forms and conjugates
WO2024129756A1 (fr) 2022-12-13 2024-06-20 Seagen Inc. Conjugués anticorps-médicament modifiés par la cystéine spécifiques d'un site
WO2025019228A1 (fr) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux entièrement humains et récepteurs antigéniques chimériques dirigés contre cd276 pour le traitement de tumeurs solides
EP4509142A1 (fr) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 comme cible dans le traitement du cancer
WO2025149947A1 (fr) 2024-01-12 2025-07-17 Seagen Inc. Conjugués anticorps-médicament
AU2025218272A1 (en) 2024-02-07 2026-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
WO2026165109A1 (fr) 2025-01-28 2026-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux tem8 et leur utilisation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991013080A1 (fr) 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides, pseudonucleotides et leurs polymeres
EP0563475B1 (fr) 1992-03-25 2000-05-31 Immunogen Inc Conjugués d'agents ciblés et de dérivés du CC-1065
ES2260570T3 (es) 1998-08-27 2006-11-01 Spirogen Limited Pirrolobenziodiazepinas dimericas.
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6472056B1 (en) 1999-07-06 2002-10-29 Northwest Coatings Corp. Radiation-cured laminate label
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
MXPA02012438A (es) * 2000-06-16 2004-09-06 Dept Of Radiation Oncology Uni Columnas extracorporeas para uso repetido, cargadas con conjugados de ligando-dibiotina.
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
ATE413407T1 (de) * 2003-03-31 2008-11-15 Council Scient Ind Res Pyrrolo(2,1-c)(1,4)benzodiazepin-dimere als antitumormittel und verfahren dafür
EP1651162B1 (fr) 2003-05-20 2015-10-21 ImmunoGen, Inc. Agents cytotoxiques ameliores contenant de nouveaux maytansinoides
AU2004284075A1 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0416511D0 (en) * 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
EP1723152B1 (fr) 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazépines
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents

Also Published As

Publication number Publication date
IL192472A0 (en) 2009-02-11
AU2007209072B2 (en) 2012-09-27
EP2371827A1 (fr) 2011-10-05
DK1981889T3 (da) 2014-04-14
CA2635482C (fr) 2012-05-22
PL1981889T3 (pl) 2014-06-30
KR20080097435A (ko) 2008-11-05
EA200870193A1 (ru) 2009-02-27
ES2457525T3 (es) 2014-04-28
AU2007209072A1 (en) 2007-08-02
GT200800147A (es) 2012-03-12
EP2386559A1 (fr) 2011-11-16
AU2007209072C1 (en) 2013-03-14
ME01814B (me) 2014-09-20
NZ569789A (en) 2011-11-25
ECSP088632A (es) 2008-08-29
NO20083427L (no) 2008-10-14
PE20071110A1 (es) 2007-12-21
HN2008001103A (es) 2011-12-01
HRP20110955T1 (hr) 2012-01-31
CN101374846A (zh) 2009-02-25
DK1813614T3 (da) 2012-01-23
EP1813614B1 (fr) 2011-10-05
DOP2007000016A (es) 2007-09-15
HRP20140307T1 (hr) 2014-06-20
NO341074B1 (no) 2017-08-21
KR101428112B1 (ko) 2014-08-07
WO2007085930A1 (fr) 2007-08-02
MY157715A (en) 2016-07-15
PT1813614E (pt) 2012-01-09
TWI389909B (zh) 2013-03-21
US20090036431A1 (en) 2009-02-05
UA97794C2 (ru) 2012-03-26
EA017196B1 (ru) 2012-10-30
JP5116696B2 (ja) 2013-01-09
PL1813614T3 (pl) 2012-03-30
JP2009524636A (ja) 2009-07-02
NI200800207A (es) 2010-07-15
CA2635482A1 (fr) 2007-08-02
MX2008009582A (es) 2008-11-26
ZA200805649B (en) 2009-11-25
TNSN08283A1 (en) 2009-10-30
EP1813614A1 (fr) 2007-08-01
EP1981889B1 (fr) 2014-01-15
PH12011502704A1 (en) 2012-05-28
SI1813614T1 (sl) 2012-01-31
TW200806668A (en) 2008-02-01
CN101374846B (zh) 2013-10-30
RS52060B (sr) 2012-04-30
CY1112495T1 (el) 2015-12-09
CR10149A (es) 2008-10-29
ES2374964T3 (es) 2012-02-23
SI1981889T1 (sl) 2014-05-30
RS53293B (sr) 2014-08-29
AR059201A1 (es) 2008-03-19
ATE527262T1 (de) 2011-10-15
EP1981889A1 (fr) 2008-10-22
BRPI0707264A2 (pt) 2011-04-26
CY1115199T1 (el) 2017-01-04
HK1129106A1 (en) 2009-11-20
PT1981889E (pt) 2014-04-29
US8163736B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
SE0402735D0 (sv) Novel compounds
MA31953B1 (fr) Nouveaux derives du thiophene.
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
TN2012000146A1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
MA32787B1 (fr) Peptides antiviraux therapeutiques
NZ553405A (en) Nucleoside phosphonate conjugates as anti-HIV agents
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
JO2282B1 (en) Oxazole derivatives
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
MA30410B1 (fr) Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique.
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
TN2011000658A1 (fr) Derives de pyrazoles, leur preparation et leur application en therapeutique
TN2010000025A1 (fr) Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
TNSN05238A1 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation pour le traitement de la douleur
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
MA32062B1 (fr) Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments